Published in J Immunol on November 15, 2006
The immune system in atherosclerosis. Nat Immunol (2011) 6.51
Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics (2009) 2.36
T cells as therapeutic targets in SLE. Nat Rev Rheumatol (2010) 1.75
Normalizing glycosphingolipids restores function in CD4+ T cells from lupus patients. J Clin Invest (2014) 1.60
Abnormalities of T cell signaling in systemic lupus erythematosus. Arthritis Res Ther (2011) 1.37
Lipid rafts in T cell signalling and disease. Semin Cell Dev Biol (2007) 1.29
Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. J Clin Invest (2011) 1.19
T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity. J Clin Invest (2015) 1.17
FcγRIIIa-Syk Co-signal Modulates CD4+ T-cell Response and Up-regulates Toll-like Receptor (TLR) Expression. J Biol Chem (2015) 1.09
Lipid rafts and T-lymphocyte function: implications for autoimmunity. FEBS Lett (2008) 1.02
T cells as a therapeutic target in SLE. Lupus (2015) 0.94
The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in rheumatologic disorders: a comprehensive review. Rheumatol Int (2011) 0.93
Lowering glycosphingolipid levels in CD4+ T cells attenuates T cell receptor signaling, cytokine production, and differentiation to the Th17 lineage. J Biol Chem (2011) 0.90
Therapeutic potential of statins in multiple sclerosis: immune modulation, neuroprotection and neurorepair. Future Neurol (2008) 0.88
Biomarkers in systemic lupus erythematosus: challenges and prospects for the future. Ther Adv Musculoskelet Dis (2013) 0.88
Increased membrane cholesterol in lymphocytes diverts T-cells toward an inflammatory response. PLoS One (2012) 0.87
Erythropoietin receptor signaling is membrane raft dependent. PLoS One (2012) 0.83
Regulation of Adaptive Immunity in Health and Disease by Cholesterol Metabolism. Curr Allergy Asthma Rep (2015) 0.81
Early High-dosage Atorvastatin Treatment Improved Serum Immune-inflammatory Markers and Functional Outcome in Acute Ischemic Strokes Classified as Large Artery Atherosclerotic Stroke: A Randomized Trial. Medicine (Baltimore) (2016) 0.81
Alterations in membrane caveolae and BKCa channel activity in skin fibroblasts in Smith-Lemli-Opitz syndrome. Mol Genet Metab (2011) 0.80
Agrin signalling contributes to cell activation and is overexpressed in T lymphocytes from lupus patients. J Immunol (2007) 0.79
A new approach to the molecular analysis of docking, priming, and regulated membrane fusion. J Chem Biol (2011) 0.79
Lipids rule: resetting lipid metabolism restores T cell function in systemic lupus erythematosus. J Clin Invest (2014) 0.77
Molecular Mechanisms for cAMP-Mediated Immunoregulation in T cells - Role of Anchored Protein Kinase A Signaling Units. Front Immunol (2016) 0.77
Atorvastatin effect on systemic lupus erythematosus disease activity: a double-blind randomized clinical trial. Clin Rheumatol (2014) 0.76
The role of tyrosine kinases in systemic lupus erythematosus and their potential as therapeutic targets. Expert Rev Clin Immunol (2014) 0.76
Statin Modulation of Human T-Cell Proliferation, IL-1β and IL-17 Production, and IFN-γ T Cell Expression: Synergy with Conventional Immunosuppressive Agents. Int J Inflam (2013) 0.76
Pathogenic immunity in systemic lupus erythematosus and atherosclerosis: common mechanisms and possible targets for intervention. J Intern Med (2015) 0.76
Update on cardiovascular disease in lupus. Curr Opin Rheumatol (2016) 0.75
Metabolic Factors that Contribute to Lupus Pathogenesis. Crit Rev Immunol (2016) 0.75
Tyrosine kinase inhibitors and mesenchymal stromal cells: effects on self-renewal, commitment and functions. Oncotarget (2016) 0.75
Regulation of T cell signalling by membrane lipids. Nat Rev Immunol (2016) 0.75
Systemic lupus erythematosus. N Engl J Med (2008) 10.22
Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med (2004) 6.48
CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity (2010) 5.13
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum (2010) 4.57
Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. Arthritis Rheum (2013) 4.02
Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.11
Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol (2007) 3.09
Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum (2003) 3.00
The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. Proc Natl Acad Sci U S A (2002) 2.72
An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum (2002) 2.54
Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med (2007) 2.47
The 'short' history of regulatory B cells. Trends Immunol (2007) 2.38
Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. J Immunol (2011) 2.31
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis (2012) 2.21
A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum (2009) 2.19
Rhubarb and reliability -- a Jane Austen view of systemic lupus erythematosus. J Rheumatol (2013) 1.98
Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet (2003) 1.98
Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc Natl Acad Sci U S A (2004) 1.95
CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med (2013) 1.89
Impact of DNA ligase IV on nonhomologous end joining pathways during class switch recombination in human cells. J Exp Med (2005) 1.84
Numerical scoring for the BILAG-2004 index. Rheumatology (Oxford) (2010) 1.83
British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum (2007) 1.74
Decreased Lyn expression and translocation to lipid raft signaling domains in B lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum (2005) 1.74
Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc Natl Acad Sci U S A (2008) 1.69
Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation (2009) 1.61
Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum (2010) 1.60
Normalizing glycosphingolipids restores function in CD4+ T cells from lupus patients. J Clin Invest (2014) 1.60
B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis. Proc Natl Acad Sci U S A (2011) 1.58
Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. Arthritis Rheum (2006) 1.56
The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. Rheumatology (Oxford) (2011) 1.55
Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus. J Clin Invest (2004) 1.52
The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. Rheumatology (Oxford) (2009) 1.52
IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J Immunol (2012) 1.47
Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study. Arthritis Res Ther (2009) 1.44
B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis (2007) 1.42
The 52 000 MW Ro/SS-A autoantigen in Sjögren's syndrome/systemic lupus erythematosus (Ro52) is an interferon-gamma inducible tripartite motif protein associated with membrane proximal structures. Immunology (2002) 1.42
Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis. Arthritis Res Ther (2012) 1.39
Germinal center B cells govern their own fate via antibody feedback. J Exp Med (2013) 1.36
B-cell-depletion therapy in SLE--what are the current prospects for its acceptance? Nat Rev Rheumatol (2009) 1.35
Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proc Natl Acad Sci U S A (2009) 1.34
Antineutrophil cytoplasmic autoantibodies in systemic lupus erythematosus. Lupus (2003) 1.32
Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrow-derived macrophages in vitro. Eur J Immunol (2005) 1.29
The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxford) (2011) 1.25
In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther (2006) 1.23
Lipid-antigen presentation by CD1d(+) B cells is essential for the maintenance of invariant natural killer T cells. Immunity (2012) 1.21
Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology (Oxford) (2011) 1.15
Respiratory manifestations of systemic lupus erythematosus: old and new concepts. Best Pract Res Clin Rheumatol (2009) 1.14
Natural IgM is required for suppression of inflammatory arthritis by apoptotic cells. J Immunol (2011) 1.14
Is alpha-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis? Arthritis Rheum (2004) 1.13
Syndromes and complications of interferon therapy. Curr Opin Rheumatol (2007) 1.13
Numerical scoring for the Classic BILAG index. Rheumatology (Oxford) (2009) 1.13
Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. Arthritis Rheum (2013) 1.12
Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum (2007) 1.12
Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology (Oxford) (2013) 1.10
Natural killer T cells in families of patients with systemic lupus erythematosus: their possible role in regulation of IGG production. Arthritis Rheum (2007) 1.10
Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study. Arthritis Rheum (2006) 1.09
Regulatory T-cells in systemic lupus erythematosus and rheumatoid arthritis. FEBS Lett (2011) 1.09
Rituximab as early therapy for pulmonary haemorrhage in systemic lupus erythematosus. Rheumatology (Oxford) (2009) 1.08
Statins for atherosclerosis--as good as it gets? N Engl J Med (2005) 1.08
Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis. Arthritis Rheum (2011) 1.08
Childhood- and adult-onset lupus: an update of similarities and differences. Expert Rev Clin Immunol (2009) 1.07
Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group. J Rheumatol (2004) 1.07
Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy. Arthritis Rheum (2012) 1.07
Reliability and validity of the myositis disease activity assessment tool. Arthritis Rheum (2008) 1.07
Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma. Nat Rev Rheumatol (2011) 1.06
Impaired recognition of apoptotic neutrophils by the C1q/calreticulin and CD91 pathway in systemic lupus erythematosus. Arthritis Rheum (2006) 1.06
Increased ubiquitination and reduced expression of LCK in T lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum (2003) 1.06
Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J Immunol (2004) 1.02
Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis (2012) 1.02
Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology (Oxford) (2011) 1.01
Type I IFN protects permissive macrophages from Legionella pneumophila infection through an IFN-gamma-independent pathway. J Immunol (2004) 1.01
Natural serum IgM maintains immunological homeostasis and prevents autoimmunity. Springer Semin Immunopathol (2004) 1.00
Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum (2013) 0.98
Global trends, potential mechanisms and early detection of organ damage in SLE. Nat Rev Rheumatol (2012) 0.97
Diagnostic criteria for polymyositis and dermatomyositis. Lancet (2003) 0.97
Common patterns of B cell perturbation and expanded V4-34 immunoglobulin gene usage in autoimmunity and infection. Autoimmunity (2004) 0.97
Increased positive selection of B1 cells and reduced B cell tolerance to intracellular antigens in c1q-deficient mice. J Immunol (2007) 0.96
Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. Arthritis Rheum (2008) 0.94
Cutting edge: selection of B lymphocyte subsets is regulated by natural IgM. J Immunol (2002) 0.94
The systemic lupus erythematosus Tri-Nation study: cumulative indirect costs. Arthritis Rheum (2007) 0.92
The yin and yang of regulatory T cells and inflammation in RA. Nat Rev Rheumatol (2010) 0.92
How do antiphospholipid antibodies bind beta2-glycoprotein I? Arthritis Rheum (2003) 0.92